The Next Phase In Oncology: FDA’s Pazdur On “Breakthrough” Drug Development

At a small press briefing on personalized medicine, FDA’s top cancer drug reviewer paints a picture of the next phase in cancer drug development.

More from Clinical Trials

More from R&D